This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MedVantx Achieves Significant Milestone Of Providing Over $600 Million Of Specialty Pharmacy Prescription Medications To Consumers

SAN DIEGO, Nov. 7, 2012 /PRNewswire/ -- MedVantx, Inc., the company that pioneered a unique direct to consumer pharmaceutical distribution channel in US physician offices announced today the Company's specialty home delivery pharmacy achieved the milestone of dispensing prescriptions valued at over $600M on an annualized basis.  The Company provides leading pharmaceutical manufacturers, physicians, health systems and payors novel distribution services, as well as fully transparent home delivery services to consumers nationwide via its state of the art pharmaceutical distribution facility located in Sioux Falls, SD.

"MedVantx is extremely excited to have achieved this significant company milestone," stated Ron Bertsch, RPh, General Manager of MedVantx Pharmacy Services.  "MedVantx has developed over 15 unique and customized prescription assistance and consumer access programs with 10 Fortune 100 companies.  These programs are designed to enable pharmaceutical manufacturers the ability to provide access to free medications to the indigent, uninsured and underinsured consumers.  Many of the products dispensed in the Company's programs are Specialty Pharmacy products consisting of high cost injectable, cold chain, or biotech medications and tend to serve patient populations that require significant care coordination.  This milestone reflects our ability to provide our customers and patients with a broad range of unique services in the market place," added Mr. Bertsch.

"The pharmaceutical industry is undergoing a structural shift from traditional brand name drugs to generic pharmaceuticals, but also to more specialty drugs—we address both these markets," stated Robert Feeney, Founder and Chief Executive Officer of MedVantx.  "The Prescription Assistance, Specialty Pharmacy and Cold Chain industry is growing rapidly with industry revenues which are expected to exceed $160 billion globally in 2013.  This rapid growth is coming at a time of significant supply chain consolidation and customers are seeking new channels.  MedVantx has carved-out a very specialized niche in the marketplace based on full financial transparency, mass customization techniques and the ability to provide novel solutions, for industry partners as well as consumers," added Mr. Feeney. 

About MedVantx, Inc.

MedVantx is an innovative consumer medication management and delivery company committed to streamlining access, reducing costs and providing helpful information to benefit patients, physicians, health plans, employers and manufacturers. The MedStart™ Connect program provides for a fully-automated, integrated, point-of-care to consumer home delivery channel focused on increasing the quality and cost effectiveness of the last non-managed pharmaceutical channel – the physician office sample closet. MedStart Connect includes free initial therapy samples of prescription and over-the-counter medication at the point of care, a consumer helpline providing drug information, adherence management services, and convenient consumer home delivery through its mail order pharmacy.  MedVantx Pharmacy Services, a wholly owned subsidiary of MedVantx, Inc., operates a state of the art pharmaceutical distribution facility located in Sioux Falls, SD.

MedVantx Pharmacy Services Contact: Ron Bertsch (605) 978-3930 ron.bertsch@medvantx.com

MedVantx Contact: JD Haldeman (858) 625-2990 ext. 130 JD.Haldeman@MedVantx.com

SOURCE MedVantx, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,340.78 -46.43 -0.27%
S&P 500 2,024.38 -5.17 -0.25%
NASDAQ 4,689.5240 +8.0270 0.17%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs